Who is sponsoring NCT04481932?

NCT04481932 is sponsored by Peking University.

What condition does NCT04481932 study?

NCT04481932 studies HER2-positive Breast Cancer.

Is NCT04481932 still recruiting?

NCT04481932 is currently recruiting now. Last updated 19 July 2020.

Last reviewed 2020-07-19 · How we verify

NCT04481932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trastuzumab Combined With Pyrotinib and Chemotherapy for Locally Advanced, Inflammatory, or Early HER2-positive Mammary glandsCancer: One Arm, Open, Phase II Clinical Study

Recruiting now Phase 2 Last updated 19 July 2020

What this trial tests

Phase 2 trial testing Trastuzumab combined with Pyrotinib and chemotherapy in HER2-positive Breast Cancer in 104 participants. Currently enrolling.

Timeline

1 July 2020

Primary endpoint
1 June 2022

1 December 2026

Quick facts

Lead sponsor	Peking University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	104
Start date	1 July 2020
Primary completion	1 June 2022
Estimated completion	1 December 2026
Sites	1 location across China

Drugs / interventions tested

Trastuzumab combined with Pyrotinib and chemotherapy — full drug profile →

Conditions studied

HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →

Sponsor

Peking University

Who can join

Adults 18 to 70, female only, with HER2-positive Breast Cancer. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

pathological complete response (pCR)
Time frame: From enrollment to 18 weeks
Breast without invasive carcinoma and carcinoma in situ or only carcinoma in situ (ypT0 or ypT0/is)

Sponsor's own description

This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate (pCR) for adenocarcinoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ, Ferraro E, Abuhadra N, Modi S. · · 2022 · cited 39× · PMID 35870237 · DOI 10.1016/j.ctrv.2022.102436
Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L, Shao W, Zhou C, Yang H, et al · · 2023 · cited 33× · PMID 37803271 · DOI 10.1186/s10020-023-00736-0
Signaling pathway dysregulation in breast cancer.
Ryspayeva D, Seyhan AA, MacDonald WJ, Purcell C, et al · · 2025 · cited 9× · PMID 40080721 · DOI 10.18632/oncotarget.28701

Verify or expand the search:

Other recruiting trials for HER2-positive Breast Cancer

Currently open trials in the same condition.

NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07377643 — IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · Phase 3 · recruiting
NCT07510802 — Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC · Phase 1, PHASE2 · recruiting
NCT07486089 — Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) · Phase 1, PHASE2 · recruiting
NCT07102381 — A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Ca · Phase 2 · recruiting

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04481932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 19 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04481932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing